Last reviewed · How we verify
NCT00664066: DELFT
DELFT (Dynepo Evaluation of Long-Term Follow-Up Treatment)
trial testing DYNEPO (epoetin delta) in Anemia in 3 participants. Terminated before completion.
30 July 2008
Quick facts
| Lead sponsor | Shire |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 3 |
| Start date | 25 April 2008 |
| Primary completion | 30 July 2008 |
| Estimated completion | 30 July 2008 |
| Sites | 2 locations across Germany |
Drugs / interventions tested
- DYNEPO (epoetin delta) — full drug profile →
Conditions studied
- Anemia — all drugs for Anemia →
- Kidney Diseases — all drugs for Kidney Diseases →
- Renal Failure, Chronic — all drugs for Renal Failure, Chronic →
- Kidney Failure, Chronic — all drugs for Kidney Failure, Chronic →
Sponsor
Shire — full company profile →
Who can join
Eligibility, any sex, with Anemia or Kidney Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a post-authorisation safety study to assess the incidence and severity of all pre-defined cardiovascular events in patients treated with DYNEPO, as well as to detect \& describe less common adverse drug reactions, and to summarise DYNEPO drug utilisation.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT00664066
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Anemia
Currently open trials in the same condition.
- NCT07422480 — A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myel · Phase 3 · recruiting
- NCT06968936 — Long-term Outcomes Sub-Study of Preoperative Combined Iron Therapy · NA · recruiting
- NCT07328191 — Quality of Life-Guided Transfusion in Refractory MDS or AML · NA · recruiting
- NCT07315295 — Maximizing the Benefits of Iron in Ready-to-Use Therapeutic Foods for Malnourished Children in Kenya · NA · recruiting
- NCT07400796 — Assessing Health System Readiness for Scaling Antenatal MMS in Cambodia · recruiting
Other Shire trials
Trials by the same sponsor.
- NCT05067868 — A Study of Replagal in Children and Adults With Fabry Disease in India · Phase 4 · recruiting
- NCT03878953 — A Clinical Study of rhPTH(1-84) Treatment in Japanese Participants With Chronic Hypoparathyroidism · Phase 3 · withdrawn
- NCT04840667 — A Study of Replagal in Treatment-naïve Adults With Fabry Disease · Phase 3 · terminated
- NCT04429984 — Post Marketing Surveillance (PMS) Study for Velaglucerase Alfa (VPRIV) in India · completed
- NCT04440488 — ARALAST NP Alpha-1 Lung Density Chronic Obstructive Pulmonary Disease-Emphysema (COPD-E) Study · Phase 4 · withdrawn
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00664066 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shire
- Last refreshed: 25 June 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00664066.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing